Skip to main content

Table 6 Patients’ characteristics and levels of CMTM1_v17 expression in patients received NAC (n = 78)

From: CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

Variable

CMTM1_v17 expression no. (%)

P value

 

High

Low

Age

  

0.315

  ≤ 55

13(40.6)

19(59.4)

 

  > 55

22(47.8)

24(52.2)

 

Gender

  

0.308

 Male

27(42.2)

37(57.8)

 

 Female

8(57.1)

6(42.9)

 

Smoking history

  

0.593

 Non-smoker

10(50.0)

10(50.0)

 

 Smoker

25(43.1)

33(56.9)

 

Histology

  

0.352

 Adenocarcinoma

13(43.3)

17(56.7)

 

 Non-adenocarcinoma

22(45.8)

26(54.2)

 

Histologic grading

  

0.465

 Poorly

15(40.5)

22(59.5)

 

 Moderate and well

20(48.8)

21(51.2)

 

Venous invasion

  

0.506

 Negative

29(46.8)

33(53.2)

 

 Positive

6(37.5)

10(62.5)

 

Pathological stage

  

0.856

 I/II

18(43.9)

23(56.1)

 

 III

17(45.9)

20(54.1)

 
  1. P value was calculated using Pearson’s χ2 test.
  2. NAC neoadjuvant chemotherapy